Supratentorial ICH — Trial Evidence

STICH (2005)

• Design: Early surgical evacuation (within 24h) vs. initial conservative treatment for spontaneous supratentorial ICH
• Result: No overall benefit of early surgery
• Subgroup signal: STICH 2005 showed a subgroup trend toward benefit for superficial lobar hematomas (depth from cortex ≤1 cm)
• Deep hemorrhages (basal ganglia, thalamus) showed no surgical benefit

STICH II (2013)

• Design: STICH II prospectively tested the STICH-2005 subgroup hypothesis, using the ≤1 cm cortical-depth criterion as entry (lobar ICH, 10–100 mL volume, no IVH)
• Result: Also negative for benefit overall — no statistically significant advantage of early surgery over conservative management
• Important caveat: 21% crossover from conservative to surgical group diluted the treatment effect
• Take-home: Even with the STICH-2005 subgroup criterion prospectively applied, routine early craniotomy for lobar ICH is NOT supported; surgery may benefit patients who deteriorate

MISTIE III (2019)

• Design: Minimally invasive surgery with stereotactic catheter + alteplase irrigation (to dissolve and drain clot) vs. standard medical care for ICH ≥30 mL
• Primary outcome: Did NOT meet endpoint (mRS 0–3 at 365 days)
• Critical secondary finding: Patients whose hematoma was reduced to <15 mL had significantly better outcomes
• Implication: The degree of clot removal matters — if sufficient evacuation is achieved, outcomes improve

ENRICH (2024)

• Design: Early minimally invasive parafascicular surgery (BrainPath device) + medical care vs. medical care alone. Initially enrolled both lobar AND anterior basal ganglia ICH (30–80 mL); the basal ganglia arm was stopped early for futility, and enrollment continued with lobar patients only
• Result: Met primary endpoint — improved utility-weighted mRS at 180 days, with benefit demonstrated in the LOBAR subgroup only
• First RCT to demonstrate benefit of surgical evacuation for supratentorial ICH
• Reinforces that technique and patient selection (lobar, accessible hematomas) are critical — deep ICH remains non-surgical

Cerebellar Hemorrhage — Surgical Emergency

• Posterior fossa is a confined space — even moderate-sized hemorrhages can cause rapid brainstem compression and death
• Surgical evacuation (suboccipital craniectomy) is indicated for:
  • Cerebellar ICH volume ≥15 mL (corresponds to the classic >3 cm diameter heuristic; 2022 AHA/ASA uses volume-based wording)
  • Neurological deterioration (declining GCS)
  • Brainstem compression (absent brainstem reflexes, new cranial nerve palsies, progressive obtundation)
  • Obstructive hydrocephalus from fourth ventricle compression
• 2022 AHA/ASA recommendation — immediate surgical evacuation, with or without EVD, is recommended for the criteria above; one of the most clear-cut surgical indications in neurology
• EVD alone is insufficient — does not address posterior fossa mass effect; must evacuate the clot
• Excellent outcomes are possible if surgery is performed before irreversible brainstem damage
• Small cerebellar hemorrhages (volume <15 mL, roughly <3 cm) without neurologic deterioration, brainstem compression, or hydrocephalus → medical management with close monitoring

General Indications for Surgical Consideration

• Deteriorating patient with accessible hematoma (lobar, superficial) despite maximal medical management
• Young patient with lobar ICH and good pre-morbid function
• Hematoma causing significant mass effect with midline shift and risk of herniation
• Underlying structural lesion identified (AVM, tumor, aneurysm) that requires surgical treatment

When NOT to Operate

• Deep hemorrhages (basal ganglia, thalamus) — surgical approach traverses eloquent tissue; no proven benefit
• Brainstem hemorrhage — not surgically accessible; devastating prognosis regardless
• Small ICH (<10 mL) with minimal or no neurological deficit — medical management is appropriate
• GCS 3–4 with bilateral fixed and dilated pupils — poor prognosis regardless of intervention (but consider goals of care)
• Large ICH (>60 mL) with GCS ≤8 — very high mortality; limited surgical benefit (controversial)